{"id":"2e7a0812-ca0d-5217-b915-789ee78574d9","stable_key":"18100170-a014-51c3-adeb-9dab4162b8cc:eae-p65-jnk","predicate":"context_dependent_observation","statement":"In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"671d5f11-3756-5687-8f31-f2403d915f8f","mechanism_event_label":"In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.","subject":{"id":"bea3c290-5d91-56da-8154-20b9599e271d","slug":"pbca-thymulin","display_name":"PBCA nanoparticle-bound thymulin formulation","entity_type_key":"chemical_species"},"object":{"id":"51ccf7f9-d3b9-5ef7-83ca-78a14399ea34","slug":"mouse-nfkb-pathway","display_name":"Mouse NF-kappa-B signaling readouts","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"671d5f11-3756-5687-8f31-f2403d915f8f","stable_key":"18100170-a014-51c3-adeb-9dab4162b8cc:eae-p65-jnk-event","event_type":"experimental_observation","label":"In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.","description":"| Relapsing-remitting experimental autoimmune encephalomyelitis in mice | PBCA-bound thymulin altered inflammatory signaling, including p65 Ser276 and JNK responses, with some effects persisting longer than free peptide. | Phosphorylation site and sampling day mattered; later p65 Ser536 differences included a nonsignificant trend. The measured p53 pathway did not respond. This is not demonstrated human multiple-sclerosis treatment. [2019 experiment](https://doi.org/10.3390/ijms20215374) |","status":"provisional","compartment":null,"participants":[{"entity":{"id":"bea3c290-5d91-56da-8154-20b9599e271d","slug":"pbca-thymulin","display_name":"PBCA nanoparticle-bound thymulin formulation","entity_type_key":"chemical_species"},"role":"tested factor","stoichiometry":null,"state_label":"PBCA-thymulin","sequence_order":0,"notes":""},{"entity":{"id":"51ccf7f9-d3b9-5ef7-83ca-78a14399ea34","slug":"mouse-nfkb-pathway","display_name":"Mouse NF-kappa-B signaling readouts","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"mixed","sequence_order":1,"notes":""},{"entity":{"id":"556ab115-21d6-55c5-97cd-adc37f22d371","slug":"mouse-jnk-assay-pool","display_name":"Mouse JNK assay pool, isoform unresolved","entity_type_key":"protein"},"role":"separate signaling readout","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"PBCA-thymulin\", \"comparator\": \"Disease controls and free-peptide comparison\", \"endpoint\": \"In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.\", \"effect_direction\": \"mixed\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse EAE; formulation, phosphorylation site and day-dependent endpoints.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice | 2019 | DOI 10.3390/ijms20215374 | PMID 31671728 | https://doi.org/10.3390/ijms20215374","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 72-72; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a716f6df-9b84-5354-b93a-c5d93229ef5c","evidence_kind":"source_excerpt","locator":"Lines 72-72","start_line":72,"end_line":72,"excerpt":"| Relapsing-remitting experimental autoimmune encephalomyelitis in mice | PBCA-bound thymulin altered inflammatory signaling, including p65 Ser276 and JNK responses, with some effects persisting longer than free peptide. | Phosphorylation site and sampling day mattered; later p65 Ser536 differences included a nonsignificant trend. The measured p53 pathway did not respond. This is not demonstrated human multiple-sclerosis treatment. [2019 experiment](https://doi.org/10.3390/ijms20215374) |","model_system":"Mouse EAE; formulation, phosphorylation site and day-dependent endpoints.","directness":"reported_statement","verification_status":"source_recorded","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e1871d49-9c6b-547b-a1bb-6e2b9270ca89","stable_key":"import-18100170-a014-51c3-adeb-9dab4162b8cc","title":"Thymulin: detailed mechanisms of action (reviewed 3 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"6e8ed0d7a5e23fc822f2ab418e0c4fb2411c01fcaa330039e8d7d93218cacc88","revision_id":"8c0e3449-9bbd-57c0-bb5e-de83f044f2ac","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}